Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?
A group of technology stocks, known as the "Magnificent Seven" -- a nod to the 1960 Western -- led stock market gains last year and has started to rebound in recent times. Which one makes the best buy for the second half?
The answer to that question is Nvidia (NASDAQ: NVDA), even though the stock has already climbed 800% over the past three years. Let's find out why this top artificial intelligence (AI) stock may still be in the early days of its growth story.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Nvidia's key position in AI
Nvidia has played a key role since the first days of the AI boom, and this is because it designs the crucial element that makes AI work: chips. They're known as graphics processing units (GPUs), and they power the fundamental step of training AI models, a process that allows those models to then handle complex tasks and solve real-world problems. So, without these chips, we wouldn't have AI. This helped Nvidia's revenue take off a few years ago, as you can see in the chart below.
NVDA Revenue (Annual) data by YCharts.
In Nvidia's earlier days, it primarily served the video gaming market, which resulted in progressive growth, but revenue levels were a far cry from today's AI-driven revenue. This is because companies realize the potential of this technology to save them time and money and even help them develop game-changing products and services, so they're pouring investment into AI. And Nvidia, as the leading chip designer, is benefiting. This potential is further illustrated by forecasts calling for the AI market to reach into the trillions of dollars in a few years from now.
Importantly, Nvidia isn't just about GPUs. The company has built an AI empire, creating software and networking tools, and it even aims to power the humanoid robots of tomorrow. This expansion is key to Nvidia's growth because it enables the company to benefit from every stage of AI development -- not just the early days of infrastructure ramp-up.
Nvidia's annual innovation
Meanwhile, Nvidia has also put the focus on innovation to ensure it stays ahead of its rivals. It has pledged to update its chips yearly and has already offered investors visibility into planned launches over the coming three years. Though rivals are carving out market share -- for example, Advanced Micro Devices recently reported a 57% increase in data center quarterly revenue -- Nvidia's innovation should keep it in the top spot. The enormous demand for AI means that others, like AMD, can succeed without truly encroaching on Nvidia's territory.
The biggest disappointment for Nvidia and investors at this point (and possibly into the future) is the situation concerning exports to China. The U.S. has blocked chip exports, cutting Nvidia out of the market that represented 13% of its revenue last year. This isn't a non-event, and if the situation remains as is, it limits Nvidia's growth opportunities to some degree. The good news is that Nvidia makes most of its revenue in the U.S. and a great deal in other locations as well, so the export situation doesn't necessarily translate to slow growth for this chip giant.
Why buy Nvidia over other Magnificent Seven players?
All this sounds positive, but why is Nvidia the best Magnificent Seven buy for the second half? Nvidia remains the best overall AI bet due to its deep presence across every stage of the technology's growth.
The world's biggest tech companies turn to Nvidia to power their platforms, and that's unlikely to change, as these customers aim to use the fastest processors available -- and those are likely to have the name Nvidia on them well into the future. Nvidia will accompany these customers as they deploy AI agents within their businesses or develop humanoid robots down the road.
At the same time, Nvidia's valuation leaves the stock plenty of room to run. Though it's inched higher in recent weeks, it still trades significantly lower than it did just a few months ago, at 36 times forward earnings estimates compared to more than 50 times.
All these elements, from Nvidia's presence across AI to its price today, support my prediction that this stock will roar higher in the second half and over the long run, too.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!*
Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
31 minutes ago
- The Market Online
AstraZeneca signals intent to join Inka Health's AI-driven oncology consortium
Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23 This content has been prepared in collaboration with Onco-Innovations Ltd . , a third-party issuer, and is intended for informational purposes only. Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology. The initiative seeks to address challenges in translational modeling, particularly during the transition from early- to late-stage clinical development, by integrating insights from pharmaceutical, data science, and clinical research sectors. AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research. The company's involvement in the exploratory phase will include joint planning, early input into project direction, and strategic alignment on key use cases. Inka Health is still ready to mingle with other global pharmaceutical companies regarding participation in the Consortium and plans to provide further updates as these discussions progress. The PROmAI initiative will leverage a wide range of multimodal data—including molecular, clinical, and imaging datasets—combined with emerging techniques in causal AI. The goal is to foster innovation in predictive oncology, improve transparency in AI applications, and support frameworks that align with both regulatory and payer expectations. For Inka Health, the Consortium represents a strategic opportunity to lead the development of next-generation AI tools in oncology. The company's proprietary platform, SynoGraph, utilizes causal inference to identify patient subgroups most likely to respond to specific treatments, thereby supporting precision medicine and optimizing clinical trial design. Onco-Innovations views AstraZeneca's interest as a strong endorsement of the Consortium's potential to shape the future of oncology research and drug development. 'This is not just about proving that AI can work in oncology-it's about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine's most complex domains,' Paul Arora, CEO of Inka Health, said in a news release. 'As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI.' Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology. Onco-Innovations (CBOE CA:ONCO) closed 12.06 per cent higher on Friday at C$2.23. Join the discussion: Find out what everybody's saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
Globe and Mail
35 minutes ago
- Globe and Mail
Public market insider selling at LQWD Technologies (LQWD)
Alex P. Guidi, a Director, disposed of 226,400 Common Shares on a direct ownership basis at a price of $8.746 on June 24th, 2025. This represents a $1,980,004 divestment of the company's shares and an account share holdings change of -13.4%. Let the insiders guide you to opportunity at
Globe and Mail
35 minutes ago
- Globe and Mail
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy Now
I'm not getting any younger. These days, I'm thinking more and more about retiring and the stream of passive income that will allow me to thrive instead of merely surviving. I'm attracted to high yields like everybody else, but there are more important factors to consider. Ares Capital (NASDAQ: ARCC), W.P. Carey (NYSE: WPC), and Realty Income (NYSE: O) have been hovering at the top of my list of dividend stocks to buy because they do more than just offer a high yield. All three of these stocks have remarkable track records when it comes to maintaining and raising their payouts. At the moment, they offer yields that are more than triple the average yield you'd receive from the average dividend payer in the S&P 500 index. Put it together, and they're hard to ignore. 1. Ares Capital Ares Capital is the largest business development company (BDC) with shares that trade publicly. These specialized entities fill in the private lending gap created by American banks that no longer lend directly to midsize businesses. Starved for capital, midsize businesses are willing to borrow at very attractive interest rates. The weighted average yield on Ares Capital's $27 billion portfolio was 9.8% at the end of March. Ares Capital isn't shy about sharing its investment income with shareholders. Just about every penny earned is paid out to a quarterly dividend that offers an 8.7% yield at recent prices. The BDC has a tendency to make extra dividend payments in times of plenty rather than commit to a permanent payout increase. Investors seeking a reliable income base will be glad to know its quarterly payout has been rising, or at least stable, since 2009. Direct lending to midsize businesses can be risky, but Ares Capital's enormous footprint in the asset management space means it has plenty of excellent borrowers to choose from. The BDC is externally managed by a subsidiary of Ares Management, a leading global alternative investment manager with around $546 billion in assets under management. Members of Ares Capital's underwriting team have over 25 years of experience on average, and it shows. At the end of March, just 0.9% of Ares Capital's total investment portfolio was on nonaccrual status. 2. W.P. Carey If you're willing to accept a smaller yield upfront in exchange for frequent payout increases, consider W.P. Carey. Shares of this diversified real estate investment trust (REIT) have been under pressure since it spun off its office building portfolio in 2023 and lowered its dividend accordingly. Throughout the Great Recession, W.P. Carey managed to raise its quarterly payout. The COVID-19 pandemic pulled the rug out from under its office portfolio, but it only lowered its payout by 19.7% in 2023, plus shareholders received new shares of Net Lease Office Properties. W.P. Carey has raised its dividend every quarter since it spun off Net Lease Office Properties. At recent prices, it offers a huge 5.7% yield that investors can reasonably expect to grow significantly in the years ahead. Its portfolio is highly diversified. It's three largest tenants combined are responsible for just 7% of total rent payments received annually. In April, management told us to expect between $4.82 and $4.92 in adjusted funds from operations (FFO), a proxy for earnings used to evaluate REITs. That's more than enough to meet a dividend commitment currently set at an annualized $3.60 and raise it further. 3. Realty Income Like W.P. Carey, Realty Income is a diversified REIT with steadily growing profits produced by a large portfolio of commercial property. Its cash flows grow reliably because annual rent escalators are written into long-term net leases that transfer all the variable expenses associated with building ownership to the tenant. At recent prices, Realty Income shares offer a 5.7% yield and confidence that comes with a very long payout raising streak. The company recently raised its monthly dividend payout for the 131st time since going public in 1994. With a 56-year operating history and 15,627 commercial properties spread throughout eight countries, Realty Income can borrow at interest rates that its smaller peers can only dream about. The company recently sold around $1.5 billion worth of euro-denominated notes at an effective rate of just 3.7%. For many companies that own their facilities, selling their buildings to Realty Income and leasing them back is an increasingly popular financing option. With the vast majority of leaseable buildings still owned by the businesses that operate in them, investors can look forward to many more years of steady payout raises. Should you invest $1,000 in Ares Capital right now? Before you buy stock in Ares Capital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ares Capital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
